Floatz logo

Cyclophosphamide

Malignant Pleural Disease

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Malignant Pleural Disease cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC
Icasp9M28Z T Cell Infusions
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC
Epigenetically Modified Autologous Tumor
National Cancer Institute (NCI)
Phase 1CC
FAPi-46
Jonsson Comprehensive Cancer Center
Phase 1CC
Allogenic tumor Cell Vaccine (K562)
National Cancer Institute (NCI)
Phase 1CC
Dfn-15
National Cancer Institute (NCI)
Phase 1CC
Doxepin
Mayo Clinic
Phase 2C
mt027
Suzhou Maximum Bio-tech Co., Ltd.
Phase 1NR

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →